Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
BrainAurora Medical Technology Limited provides system integral software solutions for hospitals and research projects in Mainland China. The company develops medical-grade digital therapy (DTx) products for cognitive impairment. It offers the evaluation and intervention of cognitive impairments to treat vascular diseases, neurodegenerative diseases, psychological disorders, and child development deficiencies. The company develops the Brain Function Information Management Platform software system, an evidence-based, medical-grade DTx product; Basic Cognitive Testing Software, an assessment of patients for basic cognitive capacity; Cognitive Ability Supplemental screening and assessment software, a solution designed to facilitate healthcare professionals assessment of patients; and Dyslexia Supplemental Screening and Assessment Software, a solution designed to facilitate the assessment of risk of developmental dyslexia in children. It also develops covid-19 induced cognitive impairment assessment and recovery training software; ADHD assessment and treatment software; quantitative cognitive assessment software for depression; depression treatment software; and cognitive impairment assessment software and cognitive impairment treatment software solutions. In addition, the company provides marketing services. BrainAurora Medical Technology Limited was founded in 2012 and is headquartered in Shaoxing, China.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.